 Amphastar currently has seven drugs under development, two drugs awaiting launch, and a base of over nine FDA-approved products in production. With the recent approval of generic ganirelix and vasopressin, which have a TAM of 850 million, AMPH could nearly double its revenue by YE 2023 with proper execution. 